| Literature DB >> 29861161 |
Shilpa S Dhar1, Dongyu Zhao2, Tao Lin3, Bingnan Gu1, Khusboo Pal1, Sarah J Wu4, Hunain Alam1, Jie Lv2, Kyuson Yun5, Vidya Gopalakrishnan6, Elsa R Flores7, Paul A Northcott8, Veena Rajaram9, Wei Li10, Ali Shilatifard11, Roy V Sillitoe3, Kaifu Chen12, Min Gyu Lee13.
Abstract
Super-enhancers are large clusters of enhancers that activate gene expression. Broad trimethyl histone H3 lysine 4 (H3K4me3) often defines active tumor suppressor genes. However, how these epigenomic signatures are regulated for tumor suppression is little understood. Here we show that brain-specific knockout of the H3K4 methyltransferase MLL4 (a COMPASS-like enzyme, also known as KMT2D) in mice spontaneously induces medulloblastoma. Mll4 loss upregulates oncogenic Ras and Notch pathways while downregulating neuronal gene expression programs. MLL4 enhances DNMT3A-catalyzed DNA methylation and SIRT1/BCL6-mediated H4K16 deacetylation, which antagonize expression of Ras activators and Notch pathway components, respectively. Notably, Mll4 loss downregulates tumor suppressor genes (e.g., Dnmt3a and Bcl6) by diminishing broad H3K4me3 and super-enhancers and also causes widespread impairment of these epigenomic signatures during medulloblastoma genesis. These findings suggest an anti-tumor role for super-enhancers and provide a unique tumor-suppressive mechanism in which MLL4 is necessary to maintain broad H3K4me3 and super-enhancers at tumor suppressor genes.Entities:
Keywords: DNA methylation; H4K16 deacetylation; MLL4; Notch; Ras; broad H3K4me3; epigenetics; histone methyltransferase; super-enhancers; tumor suppressor
Mesh:
Substances:
Year: 2018 PMID: 29861161 PMCID: PMC6528658 DOI: 10.1016/j.molcel.2018.04.028
Source DB: PubMed Journal: Mol Cell ISSN: 1097-2765 Impact factor: 17.970